[go: up one dir, main page]

WO2010060624A3 - Trockenverarbeitung und neue formen von lacosamid - Google Patents

Trockenverarbeitung und neue formen von lacosamid Download PDF

Info

Publication number
WO2010060624A3
WO2010060624A3 PCT/EP2009/008436 EP2009008436W WO2010060624A3 WO 2010060624 A3 WO2010060624 A3 WO 2010060624A3 EP 2009008436 W EP2009008436 W EP 2009008436W WO 2010060624 A3 WO2010060624 A3 WO 2010060624A3
Authority
WO
WIPO (PCT)
Prior art keywords
lacosamide
dry processing
novel forms
adhesive agent
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/008436
Other languages
English (en)
French (fr)
Other versions
WO2010060624A2 (de
Inventor
Hans-Günter Striegel
Jana Paetz
Ralph Stephan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of WO2010060624A2 publication Critical patent/WO2010060624A2/de
Publication of WO2010060624A3 publication Critical patent/WO2010060624A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft Trockenverfahren zur Herstellung von Tabletten enthaltend Lacosamid und Adhäsionsmittel. Ferner betrifft die Erfindung kompaktierte Intermediate enthaltend Lacosamid und ein Adhäsionsmittel sowie eine pharmazeutische Darreichungsform enthaltend Lacosamid in polymorpher Form R, S und/oder T. Ferner werden Verfahren zur Herstellung der polymorphen Formen R, S und T offenbart.
PCT/EP2009/008436 2008-11-27 2009-11-26 Trockenverarbeitung und neue formen von lacosamid Ceased WO2010060624A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008059155.6 2008-11-27
DE102008059155A DE102008059155A1 (de) 2008-11-27 2008-11-27 Trockenverarbeitung und neue Formen von Lacosamid

Publications (2)

Publication Number Publication Date
WO2010060624A2 WO2010060624A2 (de) 2010-06-03
WO2010060624A3 true WO2010060624A3 (de) 2011-05-12

Family

ID=41571721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/008436 Ceased WO2010060624A2 (de) 2008-11-27 2009-11-26 Trockenverarbeitung und neue formen von lacosamid

Country Status (2)

Country Link
DE (1) DE102008059155A1 (de)
WO (1) WO2010060624A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080275A1 (es) 2009-08-06 2012-03-28 Medichem Sa Formas solidas de un derivado de n-( fenilmetil) propanamida y procedimientos de preparacion
EP2496220B1 (de) 2009-11-03 2019-10-16 Lupin Limited Lacosamidformulierung mit modifizierter freisetzung
WO2011061610A2 (en) * 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
CA2817654A1 (en) * 2010-12-02 2012-06-07 Ucb Pharma Gmbh Once daily formulation of lacosamide
EP2468261A1 (de) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
EP2801352B1 (de) * 2013-05-08 2017-07-05 Sanovel Ilac Sanayi ve Ticaret A.S. Im Mund zerfallende Formulierung von Lacosamid
WO2014180895A1 (en) 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of lacosamide
CN111000812B (zh) * 2020-01-03 2021-06-18 石药集团中奇制药技术（石家庄）有限公司 一种拉考沙胺片的制备方法
CN114524746B (zh) * 2022-01-21 2022-11-11 河北广祥制药有限公司 拉考沙胺晶型的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3145414B2 (ja) 1996-03-15 2001-03-12 リサーチ コーポレイション テクノロジーズ インコーポレイテッド 鎮痙性鏡像異性アミノ酸誘導体
EP1642889A1 (de) 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAUER; FRÖMMING; FÜHRER (EDS): "Pharmazeutische Technologie", 1993, GEORG THIEME VERLAG, Stuttgart, XP002621734 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US10987324B2 (en) 2015-12-30 2021-04-27 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Also Published As

Publication number Publication date
WO2010060624A2 (de) 2010-06-03
DE102008059155A1 (de) 2010-06-02

Similar Documents

Publication Publication Date Title
WO2010060624A3 (de) Trockenverarbeitung und neue formen von lacosamid
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2009139817A3 (en) Crystalline pharmaceutical and methods of preparation and use thereof
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
WO2010031720A3 (en) Novel antibody formulation
IL188786A0 (en) Intermediate compound for synthesizing pharmaceutical agent and production method thereof
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
WO2007044950A3 (en) Crystalline forms of docetaxel and processes for their preparation
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2008092939A3 (en) Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010079045A3 (en) Crystalline salt forms of flibanserine
WO2007115929A8 (de) Thiazolyl-dihydro-quinazoline
WO2007062370A3 (en) Calcilytic compounds
WO2011067236A3 (de) Raltegravir-polymorphe
WO2011069032A3 (en) Formulations, salts and polymorphs of transnorsertraline and uses thereof
WO2010119450A3 (en) An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts
WO2007143152A3 (en) Preparation of (s)-pregabalin-nitrile
WO2009111785A3 (en) Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone and novel methods for synthesis
WO2011094434A3 (en) 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2008104957A3 (en) Novel polymorphic forms of milnacipran hydrochloride
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2008041176A3 (en) Process for the preparation of form i and form ii of ritonavir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09760497

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09760497

Country of ref document: EP

Kind code of ref document: A2